Clinical trial results for
advanced bladder or
urinary tract cancer
For certain previously untreated adults with
bladder cancer or urinary tract cancer
(urothelial carcinoma) that has spread or
cannot be removed by surgery
Clinical trial results for
advanced bladder or
urinary tract cancer
For certain previously untreated adults with
bladder cancer or urinary tract cancer
(urothelial carcinoma) that has spread or
cannot be removed by surgery
Actor portrayals.
In a clinical trial of 608 people with previously untreated advanced bladder or urinary tract cancer (urothelial carcinoma), 304 people were given OPDIVO + chemotherapy and 304 people were given chemotherapy alone. The chemotherapy medicines used for both groups in this clinical trial were cisplatin and gemcitabine.
Half the people were alive
Half the people were alive
People given OPDIVO + chemotherapy had a 22% lower risk of dying than those given chemotherapy alone.
People given OPDIVO + chemotherapy had a 38% lower risk of their cancer spreading, growing, or getting worse compared to those given chemotherapy alone.
OPDIVO + chemotherapy will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For previously untreated adults with urinary tract cancer (urothelial carcinoma) that has spread or cannot be removed by surgery
OPDIVO® (nivolumab), in combination with chemotherapy medicines cisplatin and gemcitabine, is a prescription medicine used as a first treatment for adults with urinary tract cancer (urothelial carcinoma) that has spread or cannot be removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.